JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$5.47B |
| 2 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$3.17B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$2.05B |
| 4 |
Amazon
AMZN
|
+$1.96B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.6B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$1.72B |
| 2 |
Vanguard Intermediate-Term Treasury ETF
VGIT
|
+$1.31B |
| 3 |
UnitedHealth
UNH
|
+$1.26B |
| 4 |
Automatic Data Processing
ADP
|
+$1.17B |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$1.08B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.28% |
| 2 | Technology | 17.17% |
| 3 | Healthcare | 10.79% |
| 4 | Financials | 9.36% |
| 5 | Consumer Discretionary | 8.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
ICPT
3201
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $2.63M | ﹤0.01% |
195,468
-201,335
| -51% | -$3.48M |
2014 Q1
36 quarters
|
|
|
TRAQ
3202
DELISTED
Trine II Acquisition Corp.
TRAQ
| $2.62M | ﹤0.01% |
250,000
+248,000
| +12,400% | +$2.57M |
2022 Q1
4 quarters
|
|
|
NVTA
3203
DELISTED
Invitae Corporation
NVTA
| $2.61M | ﹤0.01% |
1,937,197
+41,397
| +2% | +$81.6K |
2017 Q4
21 quarters
|
|
|
NGD
3204
DELISTED
New Gold Inc
NGD
| $2.61M | ﹤0.01% |
2,375,786
-1,406,685
| -37% | -$1.43M |
2013 Q2
39 quarters
|
|
3205
The Greenbrier Companies
GBX
$1.24B
| $2.6M | ﹤0.01% |
80,977
-441,216
| -84% | -$13.3M |
2014 Q3
34 quarters
|
|
3206
Century Communities
CCS
$1.67B
| $2.6M | ﹤0.01% |
40,742
+11,501
| +39% | +$686K |
2016 Q4
25 quarters
|
|
3207
CALL
Verizon
VZ
$191B
| $2.6M | ﹤0.01% |
66,900
-301,700
| -82% | -$11.9M |
2020 Q2
11 quarters
|
|
3208
Scorpio Tankers
STNG
$4.32B
| $2.6M | ﹤0.01% |
46,156
-3,741
| -7% | -$205K |
2015 Q4
29 quarters
|
|
3209
Embecta
EMBC
$337M
| $2.59M | ﹤0.01% |
92,081
-128,319
| -58% | -$3.64M |
2022 Q2
3 quarters
|
|
3210
Celldex Therapeutics
CLDX
$2.43B
| $2.58M | ﹤0.01% |
71,613
+23,558
| +49% | +$1.02M |
2017 Q4
21 quarters
|
|
3211
Skyward Specialty Insurance
SKWD
$2.51B
| $2.58M | ﹤0.01% |
+117,762
| New | +$2.29M |
2023 Q1
0 quarters
|
|
3212
PUT
Motorola Solutions
MSI
$75.5B
| $2.58M | ﹤0.01% |
9,000
-1,400
| -13% | -$369K |
2021 Q3
6 quarters
|
|
|
BSCO
3213
DELISTED
Invesco BulletShares 2024 Corporate Bond ETF
BSCO
| $2.57M | ﹤0.01% |
124,987
-9,024
| -7% | -$185K |
2019 Q3
14 quarters
|
|
3214
PUT
BioMarin Pharmaceuticals
BMRN
$10.9B
| $2.56M | ﹤0.01% |
26,300
| – | – |
2022 Q4
1 quarter
|
|
3215
Amplitude
AMPL
$1.85B
| $2.55M | ﹤0.01% |
205,301
+148,551
| +262% | +$1.97M |
2021 Q3
6 quarters
|
|
|
DESP
3216
DELISTED
Despegar.com
DESP
| $2.55M | ﹤0.01% |
415,868
+16,209
| +4% | +$100K |
2022 Q1
4 quarters
|
|
|
P
3217
CALL
Everpure Inc
P
$49.1B
| $2.55M | ﹤0.01% |
100,000
-162,700
| -62% | -$4.39M |
2022 Q2
3 quarters
|
|
|
ESMT
3218
DELISTED
EngageSmart, Inc.
ESMT
| $2.55M | ﹤0.01% |
132,483
+97,409
| +278% | +$1.88M |
2021 Q4
5 quarters
|
|
|
IBDQ
3219
DELISTED
iShares iBonds Dec 2025 Term Corporate ETF
IBDQ
| $2.55M | ﹤0.01% |
103,919
+30,659
| +42% | +$749K |
2019 Q4
13 quarters
|
|
|
API
3220
Agora
API
$348M
| $2.54M | ﹤0.01% |
701,895
-137,382
| -16% | -$526K |
2020 Q2
11 quarters
|
|
|
OKLO
3221
Oklo
OKLO
$7.17B
| $2.54M | ﹤0.01% |
+250,000
| New | +$2.52M |
2023 Q1
0 quarters
|
|
3222
Construction Partners
ROAD
$5.33B
| $2.53M | ﹤0.01% |
94,066
+7,957
| +9% | +$217K |
2019 Q2
15 quarters
|
|
|
DALS
3223
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
| $2.53M | ﹤0.01% |
250,000
+175,000
| +233% | +$1.76M |
2021 Q3
6 quarters
|
|
|
FFWM
3224
DELISTED
First Foundation Inc
FFWM
| $2.52M | ﹤0.01% |
338,658
+190,649
| +129% | +$2.55M |
2016 Q4
25 quarters
|
|
3225
Arhaus
ARHS
$1.41B
| $2.52M | ﹤0.01% |
+304,253
| New | +$3.67M |
2023 Q1
0 quarters
|
|
Similar funds
JP Morgan Chase's Q1 2023 Portfolio in Review
As of Q1 2023, JP Morgan Chase held 7,579 positions worth $821B, up 8.2% from $759B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
JP Morgan Chase's Q1 2023 filing shows 751 new, 3,314 increased, 2,056 reduced and 652 closed positions. Its largest new stake was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M. The largest sale was Eli Lilly, an estimated $1.72B.
By sector, the portfolio is most concentrated in Miscellaneous at 27% of assets, up from 27% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q1 2023 buy was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M.
- JP Morgan Chase added most to JPMorgan BetaBuilders Europe ETF in Q1 2023, an estimated $5.47B increase.
- JP Morgan Chase's biggest Q1 2023 reduction was Eli Lilly, cutting an estimated $1.72B.
- JP Morgan Chase fully exited IAA, Inc. Common Stock in Q1 2023, selling an estimated $155M.
- JP Morgan Chase's ten largest holdings make up 17% of its $821B portfolio in Q1 2023.
- JP Morgan Chase opened 751 new positions and closed 652 in Q1 2023.
- JP Morgan Chase's portfolio value rose 8.2% quarter-over-quarter to $821B.
Based on JP Morgan Chase's 13F filing for Q1 2023, filed 11 May 2023.